In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment.[1][2]
^Qin, S.; Bi, F.; Xu, J.; Du, C.; Fan, Q.; Zhang, L.; Tao, M.; Jiang, D.; Wang, S.; Chen, Y.; Sheng, J.; Zhuang, X.; Wu, J.; Lv, B. (2020). "P-86 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial". Annals of Oncology. 31: S117–S118. doi:10.1016/j.annonc.2020.04.168.
January 01, 1970
donafenib, sold, under, brand, name, zepsun, pharmaceutical, drug, treatment, cancer, clinical, datatrade, nameszepsunother, namescm, 4307legal, statuslegal, statusrx, chinaidentifiersiupac, name, chloro, trifluoromethyl, phenyl, carbamoylamino, phenoxy, tride. Donafenib sold under the brand name Zepsun is a pharmaceutical drug for the treatment of cancer DonafenibClinical dataTrade namesZepsunOther namesCM 4307Legal statusLegal statusRx in ChinaIdentifiersIUPAC name 4 4 4 Chloro 3 trifluoromethyl phenyl carbamoylamino phenoxy N trideuteriomethyl pyridine 2 carboxamideCAS Number1130115 44 4PubChem CID25191001DrugBankDB15414ChemSpider23937167UNII41XGO0VS1UChEMBLChEMBL4297490CompTox Dashboard EPA DTXSID90648995Chemical and physical dataFormulaC 21H 16Cl F 3N 4O 3Molar mass464 83 g mol 13D model JSmol Interactive imageSMILES 2H C 2H 2H NC O C1 NC CC C1 OC2 CC C C C2 NC O NC3 CC C C C3 Cl C F F FInChI InChI 1S C21H16ClF3N4O3 c1 26 19 30 18 11 15 8 9 27 18 32 14 5 2 12 3 6 14 28 20 31 29 13 4 7 17 22 16 10 13 21 23 24 25 h2 11H 1H3 H 26 30 H2 28 29 31 i1D3Key MLDQJTXFUGDVEO FIBGUPNXSA N In China donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment 1 2 Donafenib is a multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases 3 It is a deuterated derivative of sorafenib with improved pharmacokinetic properties 4 5 References edit Keam Susan J Duggan Sean 2021 Donafenib First Approval Drugs 81 16 1915 1920 doi 10 1007 s40265 021 01603 0 PMID 34591285 Chen Rusi Ielasi Luca Di Carlo Alma Tovoli Francesco 2023 Donafenib in hepatocellular carcinoma Drugs of Today 59 2 83 90 doi 10 1358 dot 2023 59 2 3507751 PMID 36811408 Donafenib NCI Cancer Dictionary National Cancer Institute National Institutes of Health Qin Shukui Bi Feng Gu Shanzhi Bai Yuxian Chen Zhendong Wang Zishu Ying Jieer Lu Yinying Meng Zhiqiang Pan Hongming Yang Ping Zhang Helong Chen Xi Xu Aibing Cui Chengxu Zhu Bo Wu Jian Xin Xiaoli Wang Jufeng Shan Jinlu Chen Junhui Zheng Zhendong Xu Li Wen Xiaoyu You Zhenyu Ren Zhenggang Liu Xiufeng Qiu Meng Wu Liqing Chen Feng 2021 Donafenib Versus Sorafenib in First Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma A Randomized Open Label Parallel Controlled Phase II III Trial Journal of Clinical Oncology 39 27 3002 3011 doi 10 1200 JCO 21 00163 PMC 8445562 PMID 34185551 Qin S Bi F Xu J Du C Fan Q Zhang L Tao M Jiang D Wang S Chen Y Sheng J Zhuang X Wu J Lv B 2020 P 86 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma An open label randomized parallel controlled multicentre phase II III trial Annals of Oncology 31 S117 S118 doi 10 1016 j annonc 2020 04 168 Retrieved from https en wikipedia org w index php title Donafenib amp oldid 1223515540, wikipedia, wiki, book, books, library,
